Nikos Pekiaridis | Nurphoto | Getty Images
Shares of Moderna jumped greater than 15% on Thursday after the corporate posted a surprise quarterly profit, boosted by deferred revenue and price cuts, whilst it saw slumping sales from its Covid vaccine, its only marketable product.
The outcomes cap a rocky 12 months for the biotech company and other Covid vaccine makers, which all saw revenue plunge because the world continued to emerge from the pandemic and relied less on protective shots and coverings.
Here’s what Moderna reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly often called Refinitiv:
- Earnings per share: 55 cents. That is probably not comparable to a lack of 97 cents expected by analysts.
- Revenue: $2.81 billion vs. $2.50 billion
Moderna posted net income of $217 million, or 55 cents per share, for the fourth quarter. That compares with net income of $1.47 billion, or $3.61 per share, reported for the year-ago period.
The biotech company booked fourth-quarter sales of $2.81 billion, with revenue from its Covid shot dropping 43% from the identical period a 12 months ago. That decline was primarily driven by lower vaccine volume, but was partially offset by the next average selling price of the jab, in response to Moderna.
Notably, the corporate said it recorded $600 million in deferred revenue through the quarter related to the corporate’s work with Gavi, a nongovernmental global vaccine organization that coordinated a worldwide shot distribution program.
But Moderna CFO Jamey Mock told CNBC in an interview that the deferred revenue is “sort of a nonevent” and is not “really the very best method to beat earnings.”
He noted that Moderna is more enthusiastic about its lower-than-expected cost of sales, which he called one in all the major explanation why the corporate’s earnings got here in above what some analysts were expecting.
Cost of sales were $929 million for the fourth quarter and $4.69 billion for the total 12 months. That features charges related to the corporate’s efforts to reduce manufacturing of its Covid shot and write-downs of unused doses of the vaccine.
In November, Moderna said it had expected cost of sales to are available at $5 billion for the 12 months.
“We began to see some fruits of productivity within the fourth quarter, and so that is what we’re comfortable about,” Mock said, adding that the deferred revenue from Gavi is “just pure accounting.”
Still, the deferred revenue boosted Moderna’s full-year Covid vaccine sales to $6.7 billion, an amount the corporate first unveiled in January. It booked $18 billion in revenue in 2022 and expects sales from the shot to drop even further in 2024.
The corporate noted that the vaccine won 48% of the U.S. Covid vaccine market share last 12 months. That is up from the 37% it captured in 2022.
Moderna reiterated its full-year 2024 sales guidance of roughly $4 billion. That forecast includes revenue from its vaccine against respiratory syncytial virus, or RSV, which could win U.S. Food and Drug Administration approval on May 12.
The RSV shot can have a competitive advantage since it’s the one one which is available in a pre-filled syringe, making it easier for pharmacists to manage, CEO Stephane Bancel said Thursday on CNBC’s “Squawk Box.”
“There may be so far more to Moderna than Covid, and that is what we’re enthusiastic about,” Bancel said.
The corporate will proceed to cut back expenses in 2024, Mock noted, including a projected $4.5 billion in full-year research and development expenses, down from $4.8 billion in 2023.
“We’ll increase our discipline as well,” Mock said.
Moderna has said it expects to return to sales growth in 2025 and to interrupt even by 2026, with the launch of recent products. The corporate lost $4.7 billion for the total 12 months 2023, compared with a profit of $8.4
billion the 12 months prior.
Moderna currently has 45 products in development, nine of that are in late-stage trials. They include Moderna’s combination shot targeting Covid and the flu, which could win approval as early as 2025.
The pipeline also includes Moderna’s personalized cancer vaccine, a highly anticipated shot being developed with Merck to focus on different tumor types together with the blockbuster immunotherapy Keytruda.
Don’t miss these stories from CNBC PRO: